Second international collaborative study evaluating performance characteristics of methods measuring the von Willebrand factor cleaving protease (ADAMTS-13)

Armando Tripodi, F. Peyvandi, V. Chantarangkul, R. Palla, A. Afrasiabi, M. T. Canciani, D. W. Chung, S. Ferrari, Y. Fujimura, M. Karimi, K. Kokame, J. A. Kremer Hovinga, B. Lämmle, S. F. De Meyer, B. Plaimauer, K. Vanhoorelbeke, K. Varadi, P. M. Mannucci

Research output: Contribution to journalArticle

Abstract

Background: Over the last 4years ADAMTS-13 measurement underwent dramatic progress with newer and simpler methods. Aims: Blind evaluation of newer methods for their performance characteristics. Design: The literature was searched for new methods and the authors invited to join the evaluation. Participants were provided with a set of 60 coded frozen plasmas that were prepared centrally by dilutions of one ADAMTS-13-deficient plasma (arbitrarily set at 0%) into one normal-pooled plasma (set at 100%). There were six different test plasmas ranging from 100% to 0%. Each plasma was tested 'blind'10 times by each method and results expressed as percentage vs. the local and the common standard provided by the organizer. Results: There were eight functional and three antigen assays. Linearity of observed-vs.-expected ADAMTS-13 levels assessed as r2 ranged from 0.931 to 0.998. Between-run reproducibility expressed as the (mean) CV for repeated measurements was below 10% for three methods, 10-15% for five methods and up to 20% for the remaining three. F-values (analysis of variance) calculated to assess the capacity to distinguish between ADAMTS-13 levels (the higher the F-value, the better the capacity) ranged from 3965 to 137. Between-method variability (CV) amounted to 24.8% when calculated vs. the local and to 20.5% when calculated vs. the common standard. Comparative analysis showed that functional assays employing modified von Willebrand factor peptides as substrate for ADAMTS-13 offer the best performance characteristics. Conclusions: New assays for ADAMTS-13 have the potential to make the investigation/management of patients with thrombotic microangiopathies much easier than in the past.

Original languageEnglish
Pages (from-to)1534-1541
Number of pages8
JournalJournal of Thrombosis and Haemostasis
Volume6
Issue number9
DOIs
Publication statusPublished - 2008

    Fingerprint

Keywords

  • Laboratory screening
  • Microangiopathies
  • Standardization
  • Thrombotic thrombocytopenic purpura
  • Von Willebrand factor

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Tripodi, A., Peyvandi, F., Chantarangkul, V., Palla, R., Afrasiabi, A., Canciani, M. T., Chung, D. W., Ferrari, S., Fujimura, Y., Karimi, M., Kokame, K., Kremer Hovinga, J. A., Lämmle, B., De Meyer, S. F., Plaimauer, B., Vanhoorelbeke, K., Varadi, K., & Mannucci, P. M. (2008). Second international collaborative study evaluating performance characteristics of methods measuring the von Willebrand factor cleaving protease (ADAMTS-13). Journal of Thrombosis and Haemostasis, 6(9), 1534-1541. https://doi.org/10.1111/j.1538-7836.2008.03099.x